Advances in the use of alemtuzumab in CLL

Clin Adv Hematol Oncol. 2008 Jan;6(1):23-4.
No abstract available

Publication types

  • Review

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antigens, CD / drug effects
  • Antigens, Neoplasm / drug effects
  • Antineoplastic Agents / therapeutic use*
  • CD52 Antigen
  • Clinical Trials as Topic
  • Glycoproteins / drug effects
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Remission Induction

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antigens, CD
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • CD52 Antigen
  • CD52 protein, human
  • Glycoproteins
  • Alemtuzumab